Wyeth/Progenics File Methylnaltrexone Injection NDA For Opioid-Induced Constipation
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies will meet with FDA in May to discuss new study for an oral formulation, Wyeth tells “The Pink Sheet” DAILY.
You may also be interested in...
Wyeth Plans Methylnaltrexone Studies In New Patient Populations
Data from the three additional clinical studies would be used to expand labeling for the mu-opioid receptor antagonist following its approval, Progenics tells “The Pink Sheet” DAILY.
Wyeth Plans Methylnaltrexone Studies In New Patient Populations
Data from the three additional clinical studies would be used to expand labeling for the mu-opioid receptor antagonist following its approval, Progenics tells “The Pink Sheet” DAILY.
FDA Accepts Adolor/GSK Entereg Resubmission For Postoperative Ileus
Sponsors’ response to FDA clinical holds on the alvimopan program contain “substantially the same” information as the resubmitted NDA, Adolor tells “The Pink Sheet” DAILY.